Documento
Secuelas pulmonares de COVID-19: Enfoque en la enfermedad pulmonar intersticial
Although pirfenidone slows disease progression in patients with idiopathic pulmonary fibrosis (IPF), in clinical practice, patients often cannot tolerate the recommended dose because of several adverse events. This study aimed to investigate adverse events associated with pirfenidone and factors associated with dose reduction…
Prolonged release pirfenidone pharmacokinetics is modified in cirrhosis GENESIS study.
In both clinical and experimental trials, pirfenidone (PFD) showed anti-inflammatory and antifibrogenic effects. Considering the wide variation in hepatic functional reserve in patients with cirrhosis, we decided to learn more about the pharmacokinetics of a new formulation of prolonged release PFD in this population (PR-PFD), focusing on assessing changes on AUC0–∞, AUC0–t, and Cmax.
Factors associated with dose reduction of pirfenidone in patients with idiopathic pulmonary fibrosis: A study based on realworld clinical data.
Although pirfenidone slows disease progression in patients with idiopathic pulmonary fibrosis (IPF), in clinical practice, patients often cannot tolerate the recommended dose because of several adverse events. This study aimed to investigate adverse events associated with pirfenidone and factors associated with dose reduction…
The Baveno VII concept of cirrhosis recompensation.
Tradicionalmente, la progresión de la cirrosis compensada a descompensada se ha considerado como un camino sin retorno en la historia natural de la enfermedad. Sin embargo, este punto de vista es cada vez más cuestionado por nueva evidencia sobre la regresión de la enfermedad y la recompensación hepática tras la supresión/cura de la etiología subyacente. Para crear una definición uniforme de cirrosis recompensada, los criterios estandarizados han sido establecidos por el consenso de Baveno VII, que incluyen la eliminación del factor etiológico primario, la resolución de cualquier evento descompensante y una mejora sostenida de la función hepática…
Pirfenidona en la neumonitis fibrótica por hipersensibilidad: un ensayo clínico aleatorizado doble ciego de eficacia y seguridad.
La neumonitis por hipersensibilidad (NH) es una forma inmunológicamente mediada de enfermedad pulmonar, resultante de la exposición por inhalación a una gran variedad de antígenos. En los Estados Unidos, la prevalencia anual estimada de NH oscila entre 1.67 y 2.71 casos por cada 100 000 personas. Entre el 56% y el 68% de los casos de NH cada año se consideran enfermedad crónica y entre los casos crónicos, aproximadamente el 36%-48% tienen una presentación con fibrosis pulmonar. Una gran proporción de pacientes con Neumonitis fibrótica por hipersensibilidad (NFH) desarrollan progresión sintomática, funcional y radiográfica de la enfermedad.
Idiopathic pulmonary fibrosis in the United States: time to diagnosis and treatment.
Idiopathic pulmonary fibrosis (IPF) is the most common type of fibrosing interstitial lung disease affecting an estimated 2.8–9.3 cases per 100,000 people per year. Onset generally occurs in the 7th decade of life. Traditional risk factors include age, male gender, tobacco use history, and family history….
Expectations, symptoms, and quality of life before and after 1 year of Pirfenidone treatment in patients with idiopathic pulmonary fibrosis: A single‐arm, open‐label nonrandomized study.
Antifibrotic therapies reduce lung function decline in patients with idiopathic pulmonary fibrosis (IPF). This single‐arm, open‐label, nonrandomized study aimed to determine the influence of antifibrotic treatment on patients’ reported symptoms and expectations of the therapy.
A multi-society Delphi consensus statement on new fatty liver disease nomenclature.
The principal limitations of the terms nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) are the reliance on exclusionary confounder terms and the use of potentially stigmatising language. This study set out to determine if content experts and patient advocates were in favour of a change in nomenclature and/or definition…
Global epidemiology of cirrhosis — aetiology, trends and predictions.
Cirrhosis is an important cause of morbidity and mortality in people with chronic liver disease worldwide. In 2019, cirrhosis was associated with 2.4% of global deaths. Owing to the rising prevalence of obesity and increased alcohol consumption on the one hand, and improvements in the management of hepatitis B virus and hepatitis C virus infections on the other, the epidemiology and burden of cirrhosis are changing…
